Gaithersburg, Maryland – October 2, 2019: MaxCyte, the global cell-based therapies and life sciences company, announces today its planned participation at key upcoming industry conferences. These conferences and events will provide an opportunity for MaxCyte to showcase how the Company is driving the development of the next generation of cell-based therapies with its ExPERT platform. Details are as follows:

Maryland Tech Council Bio Innovation Conference
October 7, 2019, Bethesda North Marriott Hotel & Conference Center, Rockville, Maryland
MaxCyte is a sponsor of the keynote address from John Tisdale, M.D., Chief, Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, National Institutes of Health. In addition, MaxCyte CEO Doug Doerfler is participating in a panel discussion entitled, “Cell and Gene Therapy – How We Successfully Enable Our Future,” which begins at 11:15 a.m. ET. For more information, please visit: www.marylandlifesciences.com/conference/agenda/


European Antibody Congress – Festival of Biologics
October 15 – 18, 2019, Congress Centre, Basel, Switzerland
Professor Matthias Peipp, PhD, head of a research group at the Division of Stem Cell Transplantation and Immunotherapy (Kiel, Germany) will present “Functional Characterization of Antibodies and Antibody Derivatives Produced by Scalable Flow Electroporation” on Wednesday, October 16 at 12:25 p.m. CET. For more information, please visit: www.terrapinn.com/conference/festival-of-biologics/index.stm


Consilium Strategic Communications Annual Healthcare Conference 2019
November 19, 2019, London, UK
MaxCyte CEO Doug Doerfler will present. The event will be organised by Consilium with Berenberg, Cooley & Westwicke Partners.


About MaxCyte
MaxCyte is a clinical-stage global cell-based therapies and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. MaxCyte is developing novel CARMA therapies for its own pipeline, with its first drug candidate in a Phase I clinical trial. CARMA is MaxCyte’s mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. In addition, through its life sciences business, MaxCyte leverages its Flow Electroporation Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its flow electroporation instruments worldwide, including with all of the top ten global biopharmaceutical companies. The Company now has more than 80 partnered programme licenses in cell therapy with more than 45 licensed for clinical use, including five commercial licenses. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com

 

For further information, please contact:

 

MaxCyte Inc.Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Financial Officer

 

+1 301 944 1660
UK Financial PR AdviserConsilium Strategic Communications

Mary-Jane Elliott

Chris Welsh

Sukaina Virji

+44 (0)203 709 5700

maxcyte@consilium-comms.com

US Investor RelationsJohn Woolford

john.woolford@westwicke.com

 

US Media Relations

Jamie Lacey-Moreira

jamielacey@presscommpr.com

+1 410 375 3658

 

 

+1 410 299 3310